| Description | This antibody CM25 is a N-terminal domain (NTD)-directed antibody. It is a potently neutralizing antibody against the NTD and was protective against lethal viral challenge. This product has been determined by Bio-layer interferometry and Neutralization assay. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | SARS-CoV-2 |
| Epitope | N-terminal domain (NTD) of SARS-CoV-2 spike protein |
| Affinity | 9.4 nM |
| Expression Species | HEK293F or CHO cell line |
| Conjugation | Unconjugated |
| Purity | >95% |
| Endotoxin | <1 EU/mg |
| Form | Liquid |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
| Application | ELISA; BLI; Neut |
| Application Notes | The affinity of antibody CM25 for S-ECD was determined by Bio-layer interferometry (BLI) and the KD value is 9.4 nM. The IC50 value of CM25 against SARS-CoV-2 virus is measured by in vitro Neutralization assay, its value is about 0.81 ng/mL. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | SARS-CoV-2 S |
| Alternative Name | Severe acute respiratory syndrome coronavirus 2 spike ectodomain |
| Research Area | Coronavirus Disease 2019 |
| Related Disease | Coronavirus Disease 2019 |
